Importantly, Tri-NAb exhibits high-affinity binding to tumor cells, as well as NK/CD8+ T cells, through antigen–antibody recognition mechanisms, thereby substantially augmenting cell interactions while enhancing granzyme B and perforin release by NK/CD8+ T cells for the potent killing of neighboring tumor cells. This evidence concerns the gene PRF1 and neoplasm.